Physician profile
Krister Engja
NPI 1316519747
$707.10
in general payments reported to CMS, 2019-2025
14 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $98.00 · 2023: $26.26 · 2024: $322 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $101.15 | 2024 | Vivitrol |
| Medical Device Business Services, INC. | $98.00 | 2022 | |
| Merck Sharp & Dohme LLC | $83.44 | 2023-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Novo Nordisk INC | $80.72 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.29 | 2024-2025 | Caplyta |
| Abbvie INC. | $63.57 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $51.82 | 2025 | |
| Glaxosmithkline, LLC. | $36.23 | 2024-2025 | Trelegy Ellipta |
| Scpharmaceuticals INC. | $34.40 | 2024 | |
| Axsome Therapeutics, INC. | $27.04 | 2024 | Auvelity |
| Verona Pharma, INC. | $23.16 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $16.29 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $13.50 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $13.49 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krister Engja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.